European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Tuesday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts were marginally lower late Tuesday morning, edging 0.12% lower to 1,816.92 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by lender Banco Santander (SAN) and biopharmaceutical company Cellectis (CLLS), which advanced 3.4% and 2.1%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and lender ING (ING), which increased 1.8% each.

The decliners from continental Europe were led by internet advertising firm Criteo (CRTO) and biotech company Evaxion (EVAX), which dropped 6.3% and 5.7%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company DBV Technologies (DBVT), which lost 5.6% and 3.1%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Akari Therapeutics (AKTX), which rose 15.5% and 5.8%, respectively. They were followed by pharmaceutical company GSK (GSK) and cruise line operator Carnival (CUK), which were up 2.9% and 2.4%, respectively.

The decliners from the UK and Ireland were led by communications company WPP (WPP) and biopharmaceutical company Bicycle Therapeutics (BCYC), which fell 4.1% and 3.2%, respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and alcoholic beverage company Diageo (DEO), which were down 2.2% and 1.8%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10